Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Diabetes Care|November 10, 2012
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trialJulio Rosenstock, Bogdan Balas, Bernard Charbonnel, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trialsBernard Zinman, J Hans DeVries, Bruce Bode, et al.
The American Journal of Cardiology|October 26, 2002
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitusMartin I Freed, Robert Ratner, Santica M Marcovina, et al.
Diabetes Care|October 30, 2019
Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of DiabetesSimon R Heller, John B Buse, Robert Ratner, et al.
BMJ Open Diabetes Research & Care|October 31, 2017
Statin use and risk of developing diabetes: results from the Diabetes Prevention ProgramJill P Crandall, Kieren Mather, Swapnil N Rajpathak, et al.
Diabetes|April 28, 2005
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose toleranceSteven Haffner, Marinella Temprosa, Jill Crandall, et al.
Lancet (London, England)|September 30, 2008
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialAlan Garber, Robert Henry, Robert Ratner, et al.
Diabetes Care|November 26, 2013
Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitusShannon D Sullivan, Kathleen A Jablonski, Jose C Florez, et al.
BMC Endocrine Disorders|July 31, 2009
Actos Now for the prevention of diabetes (ACT NOW) studyRalph A Defronzo, Maryann Banerji, George A Bray, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 13, 2009
Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trialMatthew R Weir, Fawn Yeh, Angela Silverman, et al.
Pageof 3